Human Nramp1 polymorphisms, which have been associated with TB resistance [62], as well as polymorphisms found in the VC transporters encoded by SLC23A1 and SLC23A2 [63], may indicate that the host genotype could impact the efficacy of VC as an adjunct therapy [64,65]. This evidence concerns the gene SLC11A1 and tuberculosis.